Iris Roth

Iris Roth, PhD, joined Zentalis in February 2023 as Chief Operating Officer. Iris has more than 20 years of experience leading cross-functional drug development teams from research through the clinic to commercialization in both the biotechnology and pharmaceutical industries. Most recently, Iris was Vice President, Medicine Development Leader at GlaxoSmithKline, where she built a portfolio of CD226 Axis immune checkpoint inhibitors including antibodies targeting CD96, TIGIT and PVRIG. Prior to GlaxoSmithKline, Iris served in senior leadership roles at various biopharmaceutical companies, including as Chief Operating Officer of Kartos Therapeutics, and Vice President, Global Medicine Leader of AstraZeneca. In these roles, she was responsible for leading the clinical development and commercial strategy for several drugs, including the registration and launch of Acerta Pharma/AstraZeneca’s Calquence® (acalabrutinib) and Genentech/Roche’s Erivedge® (vismodegib). Iris received her B.S. in Genetics from the University of California, Berkeley, and her Ph.D. in Biomedical Sciences from the University of California, San Francisco.